Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom. Show more
Location: Zeus Building, Didcot, OX11 0DF, United Kingdom | Website: https://www.barinthusbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
29.4M
52 Wk Range
$0.64 - $2.92
Previous Close
$0.72
Open
$0.70
Volume
61,549
Day Range
$0.68 - $0.74
Enterprise Value
-33.3M
Cash
74.27M
Avg Qtr Burn
-7.663M
Insider Ownership
13.37%
Institutional Own.
44.01%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VTP-300 +/- Nivolumab Details Chronic hepatitis B | Phase 2b Update | |
VTP-300 (Viral Vector Vaccine) Details Chronic Hepatitis B | Phase 2 Data readout | |
VTP-300 (Viral Vector Vaccine) Details Chronic Hepatitis B | Phase 2 Data readout | |
VTP-300 (Immune Modulator) Details Chronic Hepatitis B | Phase 2 Data readout | |
VTP-300 (Therapeutic Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 (Therapeutic HBV Vaccine) Details Chronic Hepatitis B | Phase 2 Update | |
VTP-300 + AB-729 Details Chronic hepatitis B | Phase 2a Update | |
VTP-600 (Immune Modulator) Details Non-Small Cell Lung Cancer | Phase 1/2 Data readout | |
VTP-600 Details Non-small cell lung carcinoma | Phase 1/2 Data readout | |
VTP-600 (Viral Vector Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Data readout | |
VTP-600 (Cancer Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Update | |
VTP-200 Details Human papillomavirus | Phase 1/2 Update | |
VTP-600 (Cancer Vaccine) Details Non-Small Cell Lung Cancer | Phase 1/2 Update | |
VTP-1000 Details Celiac disease | Phase 1 Data readout | |
VTP-1000 (Tolerogenic Vaccine) Details Celiac Disease | Phase 1 Data readout | |
VTP-1000 (Antigen-Specific Immunotherapy) Details Celiac Disease | Phase 1 Data readout | |
VTP-1000 (Immune Modulator) Details Celiac Disease | Phase 1 Data readout | |
VTP-1000 (Viral Vector Vaccine) Details Celiac Disease | Phase 1 Data readout | |
VTP-1000 (Immune Modulator) Details Celiac Disease | Phase 1 Data readout | |
VTP-850 Details Prostate cancer | Phase 1 Update |
